Correction: Letters on Computed Tomography Screening for Lung Cancer

Abstract

Production of Letters to the Editor by Peter Bach, Gerard Silvestri, and Claudia Henschke, on the subject of computed tomography screening for lung cancer in the April 15 issue of Clinical Cancer Research, predated the AACR policy of publishing all authors' conflict of interest disclosures. In the interest of transparency, we are publishing disclosures originally provided to AACR by Drs. Bach and Silvestri and, more recently, by Dr. Henschke.Dr. Bach has disclosed no potential conflicts of interest.Dr. Silvestri has disclosed speaker's honoraria from Olympus, ownership interest in Alveolus, and consulting relationships with Olympus and Alveolus.Dr. Henschke has the following relationship with General Electric and the National Cancer Institute (NCI):Dr. Henschke also receives research support in the form of grants and contracts from: American Legacy Foundation, Flight Attendants' Medical Research Institute, NCI, AstraZeneca, Inc., Carestream Health, Inc., and the Foundation for Lung Cancer: early detection, prevention and treatment (primary source of funding was an unrestricted gift by the Vector group, the parent company of Liggett Tobacco).The following is a listing of the patent and patent applications in which Claudia Henschke is listed as a co-inventor.Bach P: Computed tomography screening for lung cancer (letter). Clin Cancer Res 2008;14:2511.Silvestri G: Deaths among patients with screen-detected lung cancer (letter). Clin Cancer Res 2008;14:2511.Henschke C: In response (letter). Clin Cancer Res 2008;14:2511–2.